News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Cambrex Corporation (CBM) Named First Biopharmaceutical Manufacturing Partner For Pfenex Expression Technology(TM) From Dowpharma (DOW)

12/20/2005 10:32:15 AM

EAST RUTHERFORD, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Cambrex Bio Science Baltimore, Inc., a subsidiary of Cambrex Corporation , and Dowpharma(SM) contract manufacturing services, a business unit of The Dow Chemical Company , are pleased to announce they have entered into an agreement to utilize the Pfenex Expression Technology(TM), a Pseudomonas- based technology, from Dowpharma. The relationship includes an initial technology transfer production run, the establishment of a standardized technology transfer package for customer projects, and the collaborative interactions between Cambrex, Dowpharma and third-party product companies to allow for Cambrex to successfully manufacture biologic drug substances using the Pfenex Expression Technology.

"We expect Dowpharma's Pfenex Expression Technology to greatly increase protein expression levels in our customers' processes," said Frank Marchesani, Director of Sales and Business Development, Cambrex Biopharma business. "The performance of the Pfenex Expression Technology in our initial production run confirmed the power of this exciting expression technology."

"Cambrex is impressed by the superior growth performance and expression characteristics of the Pfenex technology compared to conventional Escherichia coli based systems," added Christopher Dale, Ph.D., Vice President Technology, Cambrex Biopharma business. "The complementary services offered by Dowpharma and Cambrex scientists, combined with standardized technology transfer protocols, will streamline the transition of customer projects from Dowpharma to Cambrex."

"We are pleased to work with Cambrex to help them leverage Pfenex Expression Technology to cost effectively deliver higher yields of their customers' therapeutic proteins," said Patrick Lucy, Business Leader, Microbial Biopharmaceuticals, Dowpharma. "As a leading cGMP service provider, Cambrex will be an important part of the manufacturing network supporting the Pfenex Expression Technology."

Dowpharma has an unmatched record in developing high-productivity strains for the manufacture of numerous protein products, for both clinical and industrial applications. The Pfenex Expression Technology accelerates speed to market for vaccines and biotherapeutics by improving quality, boosting yields and reducing the cost of existing microbial systems. Pfenex Expression Technology(TM) is built around specially modified strains of Pseudomonas fluorescens bacteria that increase cellular expression of recombinant proteins and peptides while maintaining critical solubility and activity characteristics. Pfenex Expression Technology consistently outperforms other microbial systems, often with yields of five to ten times the next best expression alternative.

About Cambrex

Cambrex is a global, diversified life sciences company dedicated to providing products and services to accelerate and improve the discovery and commercialization of human therapeutics. The Company employs approximately 1900 worldwide. For more information, please visit

Since the mid-1990s, Cambrex has helped customers develop their active pharmaceutical ingredients (APIs) and drug substances more efficiently and cost-effectively. The Company has diagnosed and overcome problems that clients had in their manufacturing processes, provided clinical or commercial quantities of hundreds of pharmaceutical products and provided the analytical, regulatory and other support services that clients need to shorten the time to market. More recently, the Company expanded into the product commercialization arena with sales and marketing services. The combined strength of experience, breadth of products and services and success integrating over twenty acquisitions supports the Company's strategy to move into the specialty therapeutics market.

About Dowpharma

Dowpharma(SM) serves the pharmaceutical and biopharmaceutical industries with innovative technologies, products, and services in drug discovery, development, delivery and manufacturing. Dowpharma has one of the broadest and deepest capabilities in the global outsourcing industry with services that include process development, route selection, methods development, custom solubilization, chiral capabilities, and associated analytical services, as well as manufacturing and scale-up from feasibility, through clinical trials, to commercial manufacturing.

Dowpharma manufactures small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, nucleic acid medicines, cGMP polymers, peptides and therapeutic proteins from microbial fermentation and plant-based systems. Dowpharma draws upon over 30 years of excellent cGMP regulatory compliance in the organic synthesis of APIs and pharmaceutical intermediates with the ability to provide client support in filing and validation strategies. Dowpharma operates research, process development, and manufacturing facilities in North America and Europe. More information is available at

About Dow

Dow is a leader in science and technology, providing innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $40 billion, Dow serves customers in 175 countries and a wide range of markets that are vital to human progress: food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of sustainable development, Dow and its 43,000 employees seek to balance economic, environmental and social responsibilities. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted.

(SM) Service Mark of The Dow Chemical Company

(R)(TM)* Trademark of The Dow Chemical Company ("Dow") or an affiliated company of Dow

Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions are used in connection with any discussion of future financial and operating performance. The forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and/or regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, changes in foreign exchange rates, performance of minority investments, un-collectable receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, and lack of suitable raw materials or packaging materials. For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Cambrex Corporation; Dowpharma

CONTACT: Anne-Marie Hess, Sr. Director, Investor Relations & CorporateCommunications of Cambrex, +1-201-804-3062,; orKathy W. Sweeney of Mentus for Dowpharma, +1-858-455-5500, x230,

Read at

comments powered by Disqus